Hansa Biopharma Management

Management criteria checks 2/4

Hansa Biopharma's CEO is Søren Tulstrup, appointed in Mar 2018, has a tenure of 5.83 years. total yearly compensation is SEK26.48M, comprised of 28.6% salary and 71.4% bonuses, including company stock and options. directly owns 0.06% of the company’s shares, worth SEK1.03M. The average tenure of the management team and the board of directors is 4.3 years and 4.7 years respectively.

Key information

Søren Tulstrup

Chief executive officer

kr26.5m

Total compensation

CEO salary percentage	28.6%
CEO tenure	5.8yrs
CEO ownership	0.06%
Management average tenure	4.3yrs
Board average tenure	4.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Søren Tulstrup's remuneration changed compared to Hansa Biopharma's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2023	n/a	n/a	-kr856m
Jun 30 2023	n/a	n/a	-kr759m
Mar 31 2023	n/a	n/a	-kr678m
Dec 31 2022	kr26m	kr8m	-kr611m
Sep 30 2022	n/a	n/a	-kr626m
Jun 30 2022	n/a	n/a	-kr620m
Mar 31 2022	n/a	n/a	-kr583m
Dec 31 2021	kr26m	kr7m	-kr548m
Sep 30 2021	n/a	n/a	-kr491m
Jun 30 2021	n/a	n/a	-kr465m
Mar 31 2021	n/a	n/a	-kr431m
Dec 31 2020	kr21m	kr6m	-kr421m
Sep 30 2020	n/a	n/a	-kr426m
Jun 30 2020	n/a	n/a	-kr398m
Mar 31 2020	n/a	n/a	-kr381m
Dec 31 2019	kr11m	kr5m	-kr360m
Sep 30 2019	n/a	n/a	-kr330m
Jun 30 2019	n/a	n/a	-kr298m
Mar 31 2019	n/a	n/a	-kr274m
Dec 31 2018	kr8m	kr4m	-kr248m

Compensation vs Market: Søren's total compensation ($USD2.59M) is above average for companies of similar size in the UK market ($USD746.53K).

Compensation vs Earnings: Søren's compensation has increased whilst the company is unprofitable.

CEO

Søren Tulstrup (58 yo)

5.8yrs

Tenure

kr26,481,000

Compensation

Mr. Søren Tulstrup, M.Sc, has been President and Chief Executive Officer of Hansa Biopharma AB (publ) (formerly known as Hansa Medical AB (publ)) since March 20, 2018. Mr. Tulstrup served as the Chief Exec...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Søren Tulstrup	President & CEO	5.8yrs	kr26.48m	0.060% SEK 1.0m
Donato Spota	CFO & Senior VP	4.7yrs	no data	0.011% SEK 186.1k
Christian Kjellman	Senior VP & COO	4yrs	no data	0.012% SEK 203.8k
Hitto Kaufmann	Chief Scientific Officer	less than a year	no data	no data
Eva-Maria Joed	Vice President of Finance & Administration	4.7yrs	no data	no data
Klaus Sindahl	VP & Head of Investor Relations	no data	no data	no data
Anne Lanner	Senior VP & Chief Human Resources Officer	5yrs	no data	no data
Emanuel Björne	VP & Head of Business Development	no data	no data	no data
Lena Winstedt	Head of Science	no data	no data	no data
Vincenza Nigro	VP & Head of Medical Affairs	no data	no data	no data
Achim Kaufhold	Senior VP & Chief Medical Officer	3.6yrs	no data	no data
Magnus Korsgren	VP & Head of Research and Development	2.8yrs	no data	no data

4.3yrs

Average Tenure

54yo

Average Age

Experienced Management: HNSAS's management team is considered experienced (4.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Anders Pedersen	Independent Director	5.7yrs	kr386.00k	0.0048% SEK 82.1k
Mats Blom	Independent Director	4.7yrs	kr493.00k	0.0019% SEK 32.9k
Peter Nicklin	Independent Chairman of the Board	1.6yrs	kr525.00k	0.028% SEK 475.6k
Eva Nilsagard	Independent Director	4.7yrs	kr591.00k	0.0057% SEK 98.4k
Hilary Malone	Independent Director	2.7yrs	kr698.00k	no data
Andreas Eggert	Independent Director	5.7yrs	kr578.00k	0.010% SEK 180.4k
Gunnar Tufveson	Chairman of European Medical Advisory Board in Transplantation	no data	no data	no data
Kathryn Wood	Member - European Medical Advisory Board-Transplantation & US Medical Advisory Board-Transplantation	no data	no data	no data
Christophe Legendre	Member of European Medical Advisory Board in Transplantation	no data	no data	no data
Stanley Jordan	Chairman of US Medical Advisory Board in Transplantation	no data	no data	no data
Robert Montgomery	Member of US Medical Advisory Board in Transplantation	no data	no data	no data

4.7yrs

Average Tenure

58.5yo

Average Age

Experienced Board: HNSAS's board of directors are considered experienced (4.7 years average tenure).

Hansa Biopharma Management

Management criteria checks 2/4

Key information

Recent management updates

Hansa Biopharma AB (Publ) Announces CFO Changes

Hansa Biopharma AB (publ), Annual General Meeting, Jun 27, 2024

Hansa Biopharma Nomination Committee Formed

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Recent updates

Hansa Biopharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 372.1536 million.

Hansa Biopharma AB (Publ) Announces CFO Changes

Hansa Biopharma AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024

Hansa Biopharma AB (publ), Annual General Meeting, Jun 27, 2024

Hansa Biopharma AB (Publ) Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Hansa Biopharma Announces Full Results from 16-HMedIdeS-12 Phase 2 Trial in Patients with Antibody Mediated Rejection Episodes Following Kidney Transplantation

Hansa Biopharma Nomination Committee Formed

Hansa Biopharma Announces Positive High-Level Data from the 15-HMedIdeS-09 Phase 2 Trial

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Hansa Biopharma Provides Update on ConfIdeS Phase 3 Trial of Imlifidase in Highly Sensitized Kidney Transplant Patients

Hansa Biopharma Announces Encouraging High-Level Results for First-In-Human Trial of HNSA-5487

Hitto Kaufmann Appointed Chief Scientific Officer of Hansa Biopharma, Effective 1 December 2023

Hitto Kaufmann Appointed Chief Scientific Officer of Hansa Biopharma

Hansa Biopharma AB (publ) to Report Q1, 2024 Results on Apr 17, 2024

Hansa Biopharma Announces First Patient Treated with Imlifidase in an Investigator-Initiated Phase 2 Study in Anca-Associated Vasculitis

Hansa Biopharma Receives Provisionally Approval in Australia as Desensitization Treatment in Highly Sensitized Patients Prior to Kidney Transplantation

Hansa Biopharma Announces First Patient Dosed with Imlifidase in a Global Pivotal Phase 3 Trial in Anti-Inaugular Basement Membrane (anti-GBM) Disease

First quarter 2023 earnings released

Hansa Biopharma Announces Planned Departure of Chief Scientific Officer Christian Kjellman

Hansa Biopharma Announces Positive Reimbursement Decision for Idefirix[®] (Imlifidase) in the Czech Republic

Hansa Biopharma Announces Positive Reimbursement Decision for Idefirix[®] (Imlifidase) in the Czech Republic

Hansa Biopharma AB (publ) Announces Formation of Nomination Committee

Hansa Biopharma AB (publ) has completed a Follow-on Equity Offering.

Hansa Biopharma AB (Publ) Announces Positive Reimbursement Decision in Italy for Idefirix (Imlifidase) as Desensitization Treatment for Highly Sensitized Patients in Kidney Transplantation

Hansa Biopharma AB Announces Positive Topline Data from the Imlifidase Phase 2 Study in Antibody Mediated Rejection (AMR) Episodes Post Kidney Transplantation

Hansa Biopharma AB and Partner Sarepta Therapeutics Plan to Initiate A Clinical Study with Imlifidase as A Pre-Treatment to Sarepta's SRP-9001 Gene Therapy in DMD in 2023

Hansa Biopharma AB (publ) to Report First Half, 2023 Results on Jul 20, 2023

The Scottish Medicines Consortium Recommends Use of Hansa Biopharma's Idefirix[®] (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB and Medison Pharma Announce Positive Reimbursement Decision in Poland for Idefirix in Highly Sensitized Kidney Transplant Patients

Second quarter 2022 earnings released: kr3.82 loss per share (vs kr2.98 loss in 2Q 2021)

Hansa Biopharma AB (publ) announced that it has received $70 million in funding from NovaQuest Capital Management, L.L.C.

Hansa Biopharma Announces First Patient Treated in the Post-Authorization Efficacy Study (PAES) of Idefirix® (Imlifidase) in Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB (publ) Appoints Peter Nicklin as A New Member of the Board of Director

NICE Recommends Use of Hansa Biopharma's Idefirix (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB (publ) Announces Ulf Wiinberg Not to Stand for Re-Election as Director

Hansa Biopharma Completes Enrollment in Imlifidase Phase 2 Study in Antibody Mediated Rejection (AMR) Episodes Post Kidney Transplantation

Hansa Biopharma Announces Temporary Marketing Authorization in Switzerland for Idefirix (Imlifidase) in Kidney Transplantation

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age